Skin care company Crown Aesthetics reported on Wednesday the receipt of Medical Device Single Audit Programme (MDSAP) certification upon a rigorous audit by BSI (British Standards Institute).
Following MDSAP certification, the company will continue selling SkinPen, the first FDA cleared microneedling device, in Canada, Australia, Brazil and Japan.
MDSAP allows a single regulatory audit of a medical device manufacturer's quality management system to satisfy the requirements of multiple regulatory authorities. It covers the requirements of ISO 13485:2016 plus Good Manufacturing Practices (GMP) for each applicable regulatory authority. MDSAP is validation of the company's world-class service and pursuit of quality, safety and efficiency.
Incyte receives positive CHMP opinion for Minjuvi in relapsed or refractory follicular lymphoma
Henlius and Organon secure first US approval for pertuzumab biosimilar POHERDY
BioInvent secures EMA positive opinion for Orphan Drug Designation of BI-1808 in CTCL
Lupin launches Risperidone long-acting injectable with 180-day CGT exclusivity in US market
BodyLogicMD supports recommendation to remove black box warnings on certain forms of oestrogen
Fondazione Telethon reports positive opinion for Waskyra marketing authorisation in Europe
Maxx Orthopedics Receives FDA 510(k) Clearance for Its Libertas® Bipolar Hip System
CHMP issues positive opinion for DAWNZERA in hereditary angioedema
Merck to acquire Cidara Therapeutics in USD9.2bn deal to expand antiviral portfolio
Ingenus Pharmaceuticals' generic equivalent to Premarin receives US FDA approval